GE HealthCare Introduces Signa Sprint 1.5T MRI System at ISMRM Conference
The combination of high-performance gradient technology and AI tools with the Signa Sprint MRI reportedly facilitate enhanced MRI workflow efficiencies in cardiac and oncology imaging.
Emphasizing advances with qualitative magnetic resonance imaging (MRI), diffusion-weighted imaging (DWI) and deep learning, GE HealthCare has unveiled the Signa™ Sprint 1.5T MRI system at the International Society for Magnetic Resonance in Medicine (ISMRM) 2025 conference in Honolulu, Hawaii.
Offering a high-gradient performance of 65/200 per axis, the Signa Sprint MRI platform provides enhanced visualization of sub-millimetric structures and facilitates a deeper understanding of tissue characteristics, according to GE HealthCare.
Offering a high-gradient performance of 65/200 per axis, the Signa Spirit 1.5T MRI platform combines deep learning reconstruction capabilities with enhanced diffusion-weighted imaging (DWI) for cardiac and oncology imaging applications. (Photo courtesy of GE HealthCare.)
Incorporating deep learning reconstruction capabilities, the company maintained that the Signa Sprint MRI system significantly reduces reading time for accelerated cardiac MRI scans.
“We are driven to push the boundaries of what’s possible in MRI with our ultra-premium segment, as our goal is to set a new standard in diagnostic research and precision care that allows for earlier clinical detection and treatment response,” noted Kelly Londy, the CEO of MR at GE HealthCare. “We are working to enhance diagnostic capabilities to provide highly accurate imaging with peace of mind for patients. We hope to help clinicians unlock new horizons for research in advanced imaging.”
GE HealthCare noted that Signa Sprint is pending 510(k) clearance by the Food and Drug Administration (FDA).
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
MRI Study at ARRS Raises Questions About Disparities in Detection of MASLD
May 3rd 2025New research revealed that Hispanic Americans with evidence of hepatic steatosis on MRI but no formal diagnosis of MASLD had over a fourfold higher risk of developing hepatocellular carcinoma in comparison to those who had a formal diagnosis of MASLD.
